Clinical Trials About "Labopharm" RSS

19:11 EDT 22nd October 2018 | BioPortfolio

We list hundreds of Clinical Trials about "Labopharm" on BioPortfolio. We draw our references from global clinical trials data listed on and refresh our database daily.

More Information about "Labopharm" on BioPortfolio

We have published hundreds of Labopharm news stories on BioPortfolio along with dozens of Labopharm Clinical Trials and PubMed Articles about Labopharm for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Labopharm Companies in our database. You can also find out about relevant Labopharm Drugs and Medications on this site too.

Showing "Labopharm" Clinical Trials, all 3


A Study to Compare the Relative Bioavailability of Two 200 Mg Tramadol Hydrochloride Tablet Products Under Fasting Conditions

To determine whether the test product, Labopharm Tramadol HCl Once-A-Day (OAD) 200 mg film-coated tablets, and the reference product, Labopharm Tramadol HCl OAD 200 mg uncoated tablets, are bioequivalent.

A Dose Linearity Study of the Labopharm Formulation of Tramadol HCl/Contramid®, 100 mg, 200 mg and 300 mg After A Single Oral Administration In Fasting Condition, In Healthy Human Volunteers

The purposes of this study were: - To evaluate the plasma pharmacokinetic profile of tramadol and its principal metabolite, the O-desmethyltramadol, after a single oral administration of 100, 200 and 300 mg of tramadol as the Labopharm extended-release formulation prepared with Contramid. - To assess the dose linearity of tramadol and its principal metabolite, the O-desmethyltramadol, between 100 mg and 300 mg following a single dose administra...

Comparative Bioavailability Between Two Tramadol Formulations: Study of the Better Controlled Release of a New 200 mg Once A Day (OAD) Formulation Versus Zytram® 200 mg

The main purpose of this study is to compare the pharmacokinetic profile to establish the better controlled liberation of the test product (Tramadol HCL OAD tablets of 200 mg, Labopharm) and its bioavailability in relation with the commercialised reference (Zytram® tablets of 200 mg, Zambon), single dose administered.

More From BioPortfolio on "Labopharm"

Quick Search